181 related articles for article (PubMed ID: 36830565)
1. Evidence Based on an Integrative Analysis of Multi-Omics Data on METTL7A as a Molecular Marker in Pan-Cancer.
Liu Z; Chen Y; Shen T
Biomolecules; 2023 Jan; 13(2):. PubMed ID: 36830565
[TBL] [Abstract][Full Text] [Related]
2. Pan-cancer analysis reveals potential immunological and prognostic roles of METTL7A in human cancers.
Wang B; Jiang J; Luo D; Wang X
Sci Rep; 2024 Feb; 14(1):3476. PubMed ID: 38342956
[TBL] [Abstract][Full Text] [Related]
3. The novel putative methyltransferase METTL7A as one prognostic biomarker potentially associated with immune infiltration in human renal cancer.
Yang Z; Zhang W; Li L; Hu N; Dong X; Chen Y; Cai W; Yin L; Liu F; Tang D; Dai Y
Heliyon; 2023 Apr; 9(4):e15371. PubMed ID: 37123902
[TBL] [Abstract][Full Text] [Related]
4. Multi-omics pan-cancer study of cuproptosis core gene
Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
Front Immunol; 2022; 13():981764. PubMed ID: 36605188
[TBL] [Abstract][Full Text] [Related]
5. Multi-omics Analyses Reveal Function of Apolipoprotein E in Alternative Splicing and Tumor Immune Microenvironment in Kidney Renal Clear Cell Carcinoma via Pan-cancer Analysis.
Leng X; Liu J; Jin A; Zheng H; Wu J; Zhong L; Li Q; Li D
Cell Biochem Biophys; 2024 Mar; 82(1):1-13. PubMed ID: 38182861
[TBL] [Abstract][Full Text] [Related]
6. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
Guo B; Wang Y; Liu W; Zhang S
Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
[TBL] [Abstract][Full Text] [Related]
7. Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening.
Han G; Zhao W; Song X; Kwok-Shing Ng P; Karam JA; Jonasch E; Mills GB; Zhao Z; Ding Z; Jia P
BMC Genomics; 2017 Oct; 18(Suppl 6):678. PubMed ID: 28984208
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Analysis of N6-Methyladenosine-Related IncRNAs Prognostic Signature and the Associated Immune Infiltrates in Kidney Renal Clear Cell Carcinoma.
Chen X; Wang L; Tu J; Pan X; Li Y; Yin H; Wang M; Yuan X
Crit Rev Eukaryot Gene Expr; 2022; 32(1):79-98. PubMed ID: 35377983
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of the significance of METTL7A gene in the prognosis of lung adenocarcinoma.
Pan YQ; Xiao Y; Li Z; Tao L; Chen G; Zhu JF; Lv L; Liu JC; Qi JQ; Shao A
Front Oncol; 2022; 12():1071100. PubMed ID: 36620541
[TBL] [Abstract][Full Text] [Related]
10. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer.
Chen P; Xu J; Cui Z; Wu S; Xie T; Zhang X
Front Immunol; 2023; 14():1071675. PubMed ID: 36761737
[TBL] [Abstract][Full Text] [Related]
11. Identification of epigenetic dysregulation gene markers and immune landscape in kidney renal clear cell carcinoma by comprehensive genomic analysis.
Xie L; Wu S; He R; Li S; Lai X; Wang Z
Front Immunol; 2022; 13():901662. PubMed ID: 36059531
[TBL] [Abstract][Full Text] [Related]
12. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
13. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
Sun K; Chen RX; Li JZ; Luo ZX
Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
[TBL] [Abstract][Full Text] [Related]
14. Identification of Claudin-6 as a Molecular Biomarker in Pan-Cancer Through Multiple Omics Integrative Analysis.
Zhang C; Guo C; Li Y; Liu K; Zhao Q; Ouyang L
Front Cell Dev Biol; 2021; 9():726656. PubMed ID: 34409042
[TBL] [Abstract][Full Text] [Related]
15. Decreased expression of HADH is related to poor prognosis and immune infiltration in kidney renal clear cell carcinoma.
Jiang H; Chen H; Wan P; Chen N
Genomics; 2021 Nov; 113(6):3556-3564. PubMed ID: 34391866
[TBL] [Abstract][Full Text] [Related]
16. An
Fu S; Gong B; Ding Y; Zhuang C; Chen Q; Wang S; Li Z; Ma M; Liu Y; Zhang Z; Sun T
Comb Chem High Throughput Screen; 2022; 25(13):2278-2294. PubMed ID: 35293292
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of MFN2 as a prognostic biomarker associated with immune cell infiltration in renal clear cell carcinoma.
Cheng L; Wang Z; Nie L; Yang C; Huang H; Lin J; Zhuo D
Int Immunopharmacol; 2022 Oct; 111():109169. PubMed ID: 36007389
[TBL] [Abstract][Full Text] [Related]
18. An integrative analysis of enhancer of yellow 2 homolog (ENY2) as a molecular biomarker in pan-cancer.
Chen Q; Shi X; Bao Y; Sun G; Wu S; Chen Y
Funct Integr Genomics; 2023 Mar; 23(1):72. PubMed ID: 36862319
[TBL] [Abstract][Full Text] [Related]
19. Multi-omics analysis of tumor angiogenesis characteristics and potential epigenetic regulation mechanisms in renal clear cell carcinoma.
Zheng W; Zhang S; Guo H; Chen X; Huang Z; Jiang S; Li M
Cell Commun Signal; 2021 Mar; 19(1):39. PubMed ID: 33761933
[TBL] [Abstract][Full Text] [Related]
20. A Pan-Cancer Analysis of the Oncogenic Role of
Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
Front Genet; 2022; 13():906174. PubMed ID: 35910232
[No Abstract] [Full Text] [Related]
[Next] [New Search]
